Abstract
To evaluate changes in serum prolactin and plasma and urine aldosterone after a serotonergic challenge, 8 healthy men (19 to 42 yr), taking dexamethasone (0.75 mg qid), received the serotonin precursor L-5-hydroxytryptophan (L5HTP; 100 mg qid) with the peripheral decarboxylase inhibitor carbidopa (C; 50 mq qid) or matching placebos in a randomized, crossover manner. Serum prolactin concentration increased in all subjects after L5HTP/C in comparison to placebo, mean (SD) prolactin (ng/ml) at 8 h after dosing was 19.8 ± 6.3 after L5HTP/C and 12.0 ± 3.1 after placebo (p < 0.05). In contrast, in comparison to values on placebo, L5HTP/C had no apparent effect on mean plasma concentration at all observation times; mean (SD) aldosterone (ng/dl) at 8 h after dosing was 12.0 ± 5.1 and 12.0 ± 3.8 after placebo (NS). Mean (SD) urinary aldosterone (μg/24 h), Na+(mEq/24 h) and K+(mEq/24 h) excretion were 7.0 ± 4.4,49.3 ± 30.6, 30.1 ±11.2, after L5HTP/C and 7.4 ± 5.8, 59.7 ± 23.9, 33.3 ± 7.4 after placebo (NS). Under these study conditions, subacute serotonergic stimulation with oral L5HTP/C resulted in prolactin but not aldosterone release.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Van Woert M.H., Jutkowski R., Rosenbaum D., Bowers M.B. Jr Serotonin and myoclonus. Monogr. Neural. Sci. 3, 71,1976.
Maschak C.A., Kletzky O.A., Spencer C., Artal R. Transient effect of L-5-hydroxytryptophan on pituitary function in men and women. J. Clin. Endocrinol. Metab. 56:170, 1983.
Modlinger R.S., Schonmuller J.M., Arora S.P. Stimulation of aldosterone, renin and cortisol by tryptophan. J. Clin. Endocrinol. Metab. 48: 599, 1979.
Gross M.D., Grekin R.J., Gniadek T.C., Villareal J.Z. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. N.Engl. J. Med. 305:181,1981.
Mantero F., Opocher G., Boscaro M., Armanini D. Effect of serotonin on plasma aldosterone in man. J. Endocrinol. Invest. 5: 97, 1982.
Shenker Y., Gross M., Grekin R. Central serotonergic stimulation of aldosterone secretion. J.Clin. Invest. 76: 1485, 1985.
Krieger D.T. Serotonin regulation of ACTH secretion. In: Krieger D.T. and W.F. Ganong (Eds.), ACTH and related peptides: Structure, regulation and action. The New York Academy of Sciences, New York, 1977, vol. 527, p. 297.
Udenfriend S., Titus E., Weissback H. The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J. Biol. Chem. 216: 499, 1955.
Sherman L. Serotonin and control of prolactin secretion. In: WB Essman (Eds.) Serotonin in health and disease. SP Medical and Scientific Books, New York, 1978, vol. V, p. 265.
Takahara J., Yamauchi J., Numi M., Kageyana J., Aoki Y., Fujino K., Hasimoto K., Ofuji T. Mechanism of proalctin release by 5-hydroxytryptophan. Life Sci. 29:1463, 1981.
Wenting G., Man Int Veld A., Woltiez A., Boomsma F., Shalekamp M.A.D.H. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br. Med. J. 284: 537, 1982.
Wing L., Chalmers J., West M., Bune A.J.C., Ayres B., Graham J.R. Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. J. Cardiovasc. Pharmacol. 7 (suppl. 7): 5164, 1985.
Shenker Y., Gross M.D., Grekin R.J. Peripheral serotonin2 receptor blockade does not inhibit 5-hydroxytryptophan-induced aldosterone stimulation. J. Clin. Endocrinol. Metab. 61:1201, 1985.
Drake C.R., Cary R.M. Dopamine modulates sodium-dependent aldosterone responses to angiotensin II in humans. Hypertension 6 (Suppl.): 119, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vlasses, P.H., Rotmensch, H.H., Swanson, B.N. et al. Effect of repeated doses of L-5-hydroxytryptophan and carbidopa on prolactin and aldosterone secretion in man. J Endocrinol Invest 12, 87–91 (1989). https://doi.org/10.1007/BF03349926
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349926